Clinaptis Research

Clinaptis Research

Home
Archive
About
XBI: What Survived July's Short Retreat
XBI Short Interest Monitor · $1–5B cohort · July 31, 2026 settlement
 • Bikram K. Singh
Celldex: A Positive CSU Readout May Not Be Enough
The p-value looks de-risked. Valuation hinges on whether complete response (CR) looks more like remibrutinib (~28–31%) or clears Xolair’s historical…
 • Bikram K. Singh
Praxis: Odds Favor Ulixacaltamide Approval in ET, but...
Approval is not as de-risked as the market implies — the black box remains. Beyond the FDA decision, tolerability, persistence and commercial uptake…
 • Bikram K. Singh
Structure Therapeutics: Is Aleniglipron Really Best-in-Class?
Aleniglipron's 16.3% WL headline restates to ~10–11pp on the basis FDA now requires — a real edge in. oral GLP-1 class, not an established best-in-class…
 • Bikram K. Singh
Viking Therapeutics (VKTX): Repricing VK2735
Separating the SC valuation floor from the unresolved oral opportunity through a reverse-solve valuation framework and a ~608,000-patient crossover…
 • Bikram K. Singh

July 2026

Acadia's Alzheimer's Psychosis Bet: Direction Is Priced, Resolution Is Not
We're constructive into Sep/Oct: ~70–80% odds of success, and we like the setup — the alpha's in the magnitude: fade a thin print, add on a strong one.
 • Bikram K. Singh
Lean Mass: Selectivity Is the Trap
Selectivity makes apitegromab's lean-mass result (1.9 kg preserved vs. placebo) the cleanest in obesity — and the why exactly why it hasn't proven mass…
 • Bikram K. Singh
BIIB Alzheimer’s: CELIA Validated Tau, Not the Clinical Effect Size
The reported 26% slowing likely overstates the underlying effect. That does not mean Biogen chose the wrong dose.
 • Bikram K. Singh
Where Bears Are Still Building In XBI
Why crowded shorts have already priced the bear case — and where the marginal short is actually arriving.
 • Bikram K. Singh
MPLT: Antipsychotic Efficacy Is the Floor. Tolerability Is the Trade Into Ph2 Readout
Cobenfy proved dual M1/M4 agonism works. Ph2 ZEPHYR's job is showing whether ML-007C-MA's PK-tuned tolerability edge is real — which is why the AE…
 • Bikram K. Singh
Milvexian: AF and Stroke Indications Should Be Valued Separately
A quantitative reconstruction of BMS/J&J's Phase 3 dose-selection framework, using PK/PD modeling to independently estimate each indication's…
 • Bikram K. Singh
AMLX: Ph3 PBH Readout Less Binary Than It Looks
Three independent statistical frameworks suggest 3Q26 LUCIDITY readout is materially more derisked than prevailing investor confidence implies.
 • Bikram K. Singh
© 2026 Bikram Singh · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture